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Addendum
PEDIATRIC PRIORITIES: LEGISLATIVE AND REGULATORY
INITIATIVES TO EXPAND RESEARCH ON THE USE OF
MEDICINES IN PEDIATRIC PATIENTS
MICHAEL S. LABSON, J.D.*
After this article was set for printing there was a significant development in
the Ass'n of American Physicians and Surgeons case. As noted in the article, there
was a December 16, 2002 deadline for the government to file a notice of appeal
from the court's ruling invalidating the Pediatric Rule. Prior to that deadline, the
American Academy of Pediatrics and the Elizabeth Glaser Pediatric AIDS
Foundation filed a motion to intervene in the case. These groups explained that
they wished to intervene in order to file an appeal should the government
ultimately elect not to appeal. On December 13, 2002, the court granted the
motion to intervene and the American Academy of Pediatrics and the Elizabeth
Glaser Pediatric AIDS Foundation became Intervenor-Defendants in the case. On
December 16, 2002, the government announced that it would not file an appeal,
and instead would pursue legislation to provide FDA with new statutory authority
to require pediatric studies in certain circumstances. That same day, the
intervenors filed a notice of appeal. It remains to be seen whether the appeal will
be able to move forward given that the government elected not to appeal. It also
remains to be seen whether any legislation will pass that might moot the case.
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